-
February 28th, 2021, 05:25 PM
#21
-
February 28th, 2021 05:25 PM
# ADS
-
February 28th, 2021, 08:20 PM
#22
Just curious, but what happens to the rMNA after it's been in the body for a while? Does it disintegrate to nothing or does it remain there.
-
March 1st, 2021, 09:23 AM
#23
Originally Posted by
JBen
made in India no thanks
-
March 1st, 2021, 10:45 AM
#24
-
March 1st, 2021, 11:23 AM
#25
Originally Posted by
greatwhite
++
This does not reassure me one bit.
Our Operating System
Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the "program” or “app” is our mRNA drug - the unique mRNA sequence that codes for a protein.
We have a dedicated team of several hundred scientists and engineers solely focused on advancing Moderna's platform technology. They are organized around key disciplines and work in an integrated fashion to advance knowledge surrounding mRNA science and solve for challenges that are unique to mRNA drug development. Some of these disciplines include mRNA biology, chemistry, formulation & delivery, bioinformatics and protein engineering.
https://www.modernatx.com/mrna-techn...ry-development
-
March 1st, 2021, 11:40 AM
#26
Originally Posted by
3030
made in India no thanks
Ahhh No..it's made in the good old US of A !!
In a $1 billion contract signed last year, Johnson & Johnson pledged to deliver 37 million doses by the end of March and a total of 100 million by the end of June. But the firm is still trying to scale up its production at its new Baltimore plant.
you're thinking off the :
Covishield is the name the Serum Institute uses for the vaccine developed by the British-Swedish firm AstraZeneca with Oxford University, which it mass-produces in India.
Last edited by MikePal; March 1st, 2021 at 01:48 PM.
-
March 1st, 2021, 11:56 AM
#27
What that means is they can quickly modify it, unlike old type vaccines.
But if you want to modify your own DNA just buy a CRISPR tool you can buy these all over the internet.
Originally Posted by
impact
++
This does not reassure me one bit.
Our Operating System
Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the "program” or “app” is our mRNA drug - the unique mRNA sequence that codes for a protein.
We have a dedicated team of several hundred scientists and engineers solely focused on advancing Moderna's platform technology. They are organized around key disciplines and work in an integrated fashion to advance knowledge surrounding mRNA science and solve for challenges that are unique to mRNA drug development. Some of these disciplines include mRNA biology, chemistry, formulation & delivery, bioinformatics and protein engineering.
https://www.modernatx.com/mrna-techn...ry-development
-
March 1st, 2021, 01:27 PM
#28
This is the latest offering from Astrazeneca.
Medicinal ingredients: ChAdOx1-S [recombinant]
https://covid-vaccine.canada.ca/info...accine-en.html
"Recombinant DNA (rDNA) molecules are DNA molecules formed by laboratory methods of genetic recombination (such as molecular cloning) that bring together genetic material from multiple sources, creating sequences that would not otherwise be found in the genome."
https://en.wikipedia.org/wiki/Recombinant_DNA
"Host cell proteins (HCPs) are process-related protein impurities that are produced by the host organism during biotherapeutic manufacturing and production. During the purification process, a majority of produced HCPs are removed from the final product (>99% of impurities removed). However, residual HCPs still remain in the final distributed pharmaceutical drug. Examples of HCPs that may remain in the desired pharmaceutical product include: monoclonal antibodies (mAbs), antibody-drug-conjugates (ADCs), therapeutic proteins, vaccines, and other protein-based biopharmaceuticals.[1][2][3]
HCPs may cause immunogenicity in individuals or reduce the potency, stability or overall effectiveness of a drug. National regulatory organisations, such as the FDA and EMA provide guidelines on acceptable levels of HCPs that may remain in pharmaceutical products before they are made available to the public. Currently, the acceptable level of HCPs in pharmaceutical drugs range from 1-100ppm (1–100 ng/mg product). However, the accepted level of HCPs in a final product is evaluated on a case-by-case basis, and depends on multiple factors including: dose, frequency of drug administration, type of drug and severity of disease.
The acceptable range of HCPs in a final pharmaceutical product is large due to limitations with the detection and analytical methods that currently exist. [4]Analysis of HCPs is complex as the HCP mixture consists of a large variety of protein species, all of which are unique to the specific host organisms, and unrelated to the intended and desired recombinant protein. [5] Analysing these large varieties of protein species at very minute concentrations is difficult and requires extremely sensitive equipment which has not been fully developed yet. The reason that HCP levels need to be monitored is due to the uncertain effects they have on the body. At trace amounts, the effects of HCPs on patients are unknown and specific HCPs may affect protein stability and drug effectiveness, or cause immunogenicity in patients. [6][7] If the stability of the drug is affected, durability of the active substance in the pharmaceutical product could decrease. The effects that the drug is intended to have on patients could also possibly be increased or decreased, leading to health complications that may arise. The degree of immunogenicity on a long-term basis is difficult, and almost impossible, to determine and consequences can include severe threats to the patient’s health. [5]"
https://en.wikipedia.org/wiki/Host_cell_protein
Reply With Quote
